Professor Richards will be speaking today (7 December) at the NICE annual conference in Birmingham and will highlight the findings of a report on the use of cancer drugs recommended by NICE.
In addition to the reduction in variation of care, the results also indicate that the uptake of cancer drugs continues to rise following a positive NICE appraisal and that there is no evidence of patients being denied access to NICE recommended cancer drugs.
The announcement coincides with the publication of final draft guidance on the use of gemcitabine, the thirty-fourth cancer drug recommended by NICE.
Andrea Sutcliffe, deputy chief executive of NICE said: ‘Those who criticise NICE on the few occasions that we don’t recommend drugs should consider the bigger picture.’
In addition to the reduction in variation of care, the results also indicate that the uptake of cancer drugs continues to rise following a positive NICE appraisal and that there is no evidence of patients being denied access to NICE recommended cancer drugs.
The announcement coincides with the publication of final draft guidance on the use of gemcitabine, the thirty-fourth cancer drug recommended by NICE.
Andrea Sutcliffe, deputy chief executive of NICE said: ‘Those who criticise NICE on the few occasions that we don’t recommend drugs should consider the bigger picture.’
